EMA Issues Brexit Guidance
Print
06 June 2017
BioPharm International
On May 31, 2017, the European Medicines Agency (EMA) and the European Commission published guidance on how pharmaceutical companies can prepare for Brexit. The guidance offers information on centralized procedures and other agency activities. The guidance is one in a series of guidance documents the agency plans to publish on the effects of the United Kingdom’s withdrawal from the European Union.
Specifically, the guidance answers some of the industry’s questions regarding the implication of Brexit on marketing authorizations, orphan drug designations, and pharmacovigilance. The document address concerns regarding the location of personnel, documents, and manufacturing facilities currently located in the UK.
All Portfolio
MEDIA CENTER
-
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.